Ascendis Pharma is a global biopharmaceutical company headquartered in Copenhagen, Denmark, specializing in the development of innovative therapies using its proprietary TransCon technology platform. The company focuses on addressing unmet medical needs across endocrinology, rare diseases, and oncology. Its pipeline includes TransCon hGH for growth hormone deficiency, TransCon CNP for achondroplasia, and TransCon PTH for hypoparathyroidism, along with oncology candidates in development. Ascendis conducts clinical trials across the United States, Europe, and multinational markets, with strategic partnerships extending development efforts to Asia through entities like VISEN Pharmaceuticals in Greater China and collaborations in Japan. The company operates research facilities in Germany and offices throughout Europe and the United States, maintaining a commitment to improving treatment safety, efficacy, tolerability, and patient convenience through its innovative drug development approach.